mothertobaby tirzepatide fact sheet pregnancy 2025 and Can the new diabetes and

Bloating is one of the most reported digestive side effects of tirzepatide

As a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor (GLP-1R) agonist, tirzepatide offers unparalleled efficacy in blood sugar control and weight management for individuals with diabetes

In clinical trials it produced some of the largest weight-loss and glycemic results of any incretin therapy, with a long half-life that supports a single weekly subcutaneous injection and a stepwise titration that keeps gastrointestinal effects manageable

At the new studys conclusion, researchers found that the reduction in major adverse cardiac event risk found during their 2023 study was similar regardless of how much a study participants weight was at the start of the trial and how much weight they lost over the first 4.5 months of taking semaglutide

This reflects body composition changes as fat decreases and lean tissue is preserved

Some people sail through this phase with minimal side effects, while others find it challenging